1. Home
  2. DMAC

as 11-21-2024 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Founded: 2000 Country:
United States
United States
Employees: N/A City: MINNEAPOLIS
Market Cap: 172.7M IPO Year: N/A
Target Price: $7.00 AVG Volume (30 days): 46.2K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.56 EPS Growth: N/A
52 Week Low/High: $2.14 - $4.95 Next Earning Date: 11-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

DMAC Daily Stock ML Predictions

Share on Social Networks: